Cyclic hydroxamic acids as inhibitors of matrix metalloproteinases and/or TNF- &agr; converting enzyme (TACE)
US6740649B2 · kind B2 · utility
15Cited by
4References
49Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 16, 2002 |
| Grant date | May 25, 2004 |
| Priority date | — |
| Expiry date | Sep 16, 2022 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D491/04
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The present application describes novel cyclic hydroxamic acids of formula I: or pharmaceutically acceptable salt forms thereof, wherein ring B is a 5-7 membered cyclic system containing from 0-2 heteroatoms selected from O, N, NR1, and S(O)p, and 0-1 carbonyl groups and the other variables are defined in the present specification, which are useful as inhibitors of matrix metalloproteinases (MMP), TNF-&agr; converting enzyme (TACE), aggrecanase or a combination thereof, pharmaceutical compositions containing the same, and methods of using the same.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.